

Appendix eTable 1: Relationship between labeled and unlabeled test choice- balance sheet group (n=302)

	Unlabeled test choice		Totals
	No PSA	PSA	
Labelled test choice			
No PSA	84	20	104
PSA	86	112	198
Totals	170	132	302

Appendix eTable 2: Relationship between highest ranked attribute and most important attribute from single post-task question (n=307)

	Most important attribute – single post-task question				Totals
	Incidence	Mortality	Biopsy	Impotence / Incontinence	
Highest ranked attribute					
Incidence	41	21	7	4	73
Mortality	18	129	8	7	162
Biopsy	7	10	9	3	29
Impotence / Incontinence	3	7	3	30	43
Totals	69	167	27	44	307

Appendix eTable 3: Mean utilities from DCE

Attribute - Level	Mean utility (95%CI)	% respondents ranked first
Chance of death from prostate cancer		53.5%
2 in 1000	3.0407 (2.8379 , 3.1525)	
3 in 1000	-1.0091 (-1.1306 , -0.9422)	
4 in 1000	-2.0316 (-2.1698 , -1.955)	
Chance of diagnosis		20.8%
40 in 1000	2.4736 (2.1732, 2.6392)	
60 in 1000	-0.7295 (-0.8850, -0.6438)	
80 in 1000	-1.7441 (-1.9240, -1.6450)	
Chance of requiring a biopsy as a result of screening		15.8%
0 in 1000	1.3672 (1.0659 , 1.5332)	
240 in 1000	-0.8259 (-0.9887 , -0.7362)	
330 in 1000	-0.5413 (-0.7376 , -0.4331)	
Chance of developing impotence or incontinence as a result of screening		9.9%
0 in 1000	2.6974 (2.4842 , 2.8148)	
10 in 1000	-1.1706 (-1.2972 , -1.1008)	
20 in 1000	-1.5268 (-1.6391 , -1.4649)	